Browsing by Author Pavlick, Anna C.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)Citation
2006Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group.Millward, Michael; Bedikian, Agop Y.; Conry, Robert; DeConti, Ronald; Gore, Martin; Haluska, Frank G.; Hersey, Peter; Hersh, Evan M.; Kirkwood, John M; Pavlick, Anna C.; Pehamberger, Hubert; Trefzer, Uwe; MedicineBcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group., JOURNAL OF CLINICAL ONCOLOGY 2005, vol.24,(29),2006,pp 4738-4745
2012Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trialKefford, Richard (Rick); Long, Georgina; Arkenau, Tobias; Brown, Michael P.; et al, various; Falchook, GErald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; O'Day, Steven; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial, The Lancet, vol.379, 9829, 2012,pp 1893-1901
2014Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436)Kefford, Richard (Rick); Long, Georgina; Arkenau, Hendrik-Tobias; Brown, Michael P.; Chin, Melvin; et al, .; Falchook, Gerald; Hamid, Omid; Infante, Jeffrey; Kim, Kevin; Kurzrock, Razelle; Millward, Michael; Pavlick, Anna C.; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF-inhibitor Dabrafenib (GSK2118436), Clinical Cancer Research, vol.20, 17, 2014,pp 4449-4458
2013Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic MelanomaHersey, Peter; Long, Georgina; et al, Various; Flaherty, Keith; Gonzalez, Rene; Hutson, Thomas; Kim, Kevin; McArthur, Grant A.; Moschos, Stergios; Pavlick, Anna C.; Schuchter, Lynn; Trunzer, Kerstin; Weber, Jeffrey; Northern Clinical School: Surgery; Central Clinical School: The Sydney Cancer CentrePharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, 14, 2013,pp 1767-1774
2009A Phase 2, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic MelanomaKefford, Richard (Rick); Dar, Mohammed; Kathman, Steven; Kirkwood, John M; Laubscher, Kevin; Logan, Theodore F.; Mainwaring, Paul; Millward, Michael; Pavlick, Anna C.; Tarhini, Ahmad; Western Clinical School: Westmead Millennium InstituteA Phase 2, Randomized Study of SB-485232, rhIL-18, in Patients With Previously Untreated Metastatic Melanoma, Cancer, vol.115, 4,pp 859-868
2013Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorKefford, Richard (Rick); Long, Georgina; et al, Various; Fecher, Leslie A.; Gonzalez, Rene; Hwu, Patrick; Infante, Jeffrey; Kim, Kevin; McArthur, Grant A.; Millward, Michael; Pavlick, Anna C.; Ribas, Antoni; Sosman, Jeffrey; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentrePhase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor, Journal of Clinical Oncology, vol.31, 4, 2013,pp 482-489
2010A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue CorrelatesHamilton, Anne; Buckley, Michael; Christos, Paul; Goldberg, Lauren; Liebes, Leonard; Min, Christina; Osman, Iman; Ott, Patrick; Pavlick, Anna C.; Polsky, David; Safarzadeh-Amiri, Sara; Wright, John J.; Yee, Herman; Yoon, Joanne; Central Clinical School: MedicineA Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates, PLoS One, vol.5, 12,pp e15588 - 1-e15588 - 9
2010A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanomaHamilton, Anne; Christos, Paul; Doyle, Austin; Haas, Naomi; Jones, Amanda; Liddell, Sandra; Millward, Michael; Muggia, Franco; Ott, Patrick; Pavlick, Anna C.; Shore, Tsiporah; Central Clinical School: MedicineA phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma, PLoS One, vol.5, 1,pp e8714-1-e8714-7
2012Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibHersey, Peter; Kefford, Richard (Rick); et al, Various; Flaherty, Keith; Gonzalez, Rene; Hutson, Thomas; Kim, Kevin; McArthur, Grant A.; Moschos, Stergios; Pavlick, Anna C.; Schuchter, Lynn; Sosman, Jeffrey; Weber, Jeffrey; Northern Clinical School: Surgery; Western Clinical School: Westmead Millennium InstituteSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib, New England Journal of Medicine, vol.366, 8, 2012,pp 707-714